BioAlliance Strengthens the Protection of Livatag(R) (doxorubicin Transdrug(TM) with the Grant of a European Patent

Published: Jul 12, 2011

PARIS--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Euronext Paris: BIO), a company dedicated to specialty and orphan oncology products, today announces the grant of a European patent protecting its Transdrug™ nanotechnology. This new industrial property notably covers Livatag®, the first product of its « Orphan oncology products » portfolio until 2023.

Back to news